Tue . 19 Oct 2019
TR | RU | UK | KK | BE |

Multi-drug-resistant tuberculosis

multi-drug-resistant tuberculosis, what is multi-drug-resistant tuberculosis
Multi-drug-resistant tuberculosis MDR-TB is a form of tuberculosis TB infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications drugs, isoniazid and rifampin Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB XDR-TB

Tuberculosis is caused by infection with the bacteria Mycobacterium tuberculosis Almost one in four people in the world are infected with TB bacteria Only when the bacteria become active do people become ill with TB Bacteria become active as a result of anything that can reduce the person's immunity, such as HIV, advancing age, diabetes or other immunocompromising illnesses TB can usually be treated with a course of four standard, or first-line, anti-TB drugs ie, isoniazid, rifampin and any fluoroquinolone

However, beginning with the first antibiotic treatment for TB in 1943, some strains of the TB bacteria developed resistance to the standard drugs through genetic changes see mechanisms Currently the majority of multidrug-resistant cases of TB are due to one strain of TB bacteria called the Beijing lineage This process accelerates if incorrect or inadequate treatments are used, leading to the development and spread of multidrug-resistant TB MDR-TB Incorrect or inadequate treatment may be due to use of the wrong medications, use of only one medication standard treatment is at least two drugs, not taking medication consistently or for the full treatment period treatment is required for several months Treatment of MDR-TB requires second-line drugs ie, fluoroquinolones, aminoglycosides, and others, which in general are less effective, more toxic and much more expensive than first-line drugs Treatment schedules for MDR-TB involving fluoroquinolones and aminoglycosides can run for 2 years, compared to the 6 months of first-line drug treatment, and cost over $100,000 USDIf these second-line drugs are prescribed or taken incorrectly, further resistance can develop leading to XDR-TB

Resistant strains of TB are already present in the population, so MDR-TB can be directly transmitted from an infected person to an uninfected person In this case a previously untreated person develops a new case of MDR-TB This is known as primary MDR-TB, and is responsible for up to 75% of cases Acquired MDR-TB develops when a person with a non-resistant strain of TB is treated inadequately, resulting in the development of antibiotic resistance in the TB bacteria infecting them These people can in turn infect other people with MDR-TB

MDR-TB caused an estimated 480,000 new TB cases and 250,000 deaths in 2015 MDR-TB accounts for 33% of all new TB cases worldwide Resistant forms of TB bacteria, either MDR-TB or rifampin-resistant TB, cause 39% of new TB cases and 21% of previously treated TB cases Globally, most MDR-TB cases occur in South America, Southern Africa, India, China, and the former Soviet Union

Treatment of MDR-TB requires treatment with second-line drugs, usually four or more anti-TB drugs for a minimum of 6 months, and possibly extending for 18–24 months if rifampin resistance has been identified in the specific strain of TB with which the patient has been infected Under ideal program conditions, MDR-TB cure rates can approach 70%


  • 1 Mechanism of drug resistance
  • 2 Extensively drug-resistant TB
  • 3 Prevention
    • 31 DOTS-Plus
  • 4 Treatment
  • 5 Epidemiology
    • 51 Russian prisons
      • 511 Contributing factors
      • 512 Policy impacts
  • 6 See also
  • 7 References
  • 8 External links

Mechanism of drug resistance

The TB bacteria has natural defenses against some drugs, and can acquire drug resistance through genetic mutations The bacteria does not have the ability to transfer genes for resistance between organisms through plasmids see horizontal transfer Some mechanisms of drug resistance include:

  1. Cell wall: The cell wall of M tuberculosis TB contains complex lipid molecules which act as a barrier to stop drugs from entering the cell
  2. Drug modifying & inactivating enzymes: The TB genome codes for enzymes proteins that inactivate drug molecules These enzymes usually phosphorylate, acetylate, or adenylate drug compounds
  3. Drug efflux systems: The TB cell contains molecular systems that actively pump drug molecules out of the cell
  4. Mutations: Spontaneous mutations in the TB genome can alter proteins which are the target of drugs, making the bacteria drug resistant

One example is a mutation in the rpoB gene, which encodes the beta subunit of the bacteria's RNA polymerase In non-resistant TB, rifampin binds the beta subunit of RNA polymerase and disrupt transcription elongation Mutation in the rpoB gene changes the sequence of amino acids and eventual conformation of the beta subunit In this case rifampin can no longer bind or prevent transcription, and the bacteria is resistant

Other mutations make the bacterium resistant to other drugs For example, there are many mutations that confer resistance to isoniazid INH, including in the genes katG, inhA, ahpC and others Amino acid replacements in the NADH binding site of InhA apparently result in INH resistance by preventing the inhibition of mycolic acid biosynthesis, which the bacterium uses in its cell wall Mutations in the katG gene make the enzyme catalase peroxidase unable to convert INH to its biologically active form Hence, INH is ineffective and the bacteria is resistant The discovery of new molecular targets is essential to overcome drug resistant problems

In some TB bacteria, the acquisition of these mutations can be explained other mutations in the DNA recombination, recognition and repair machinery Mutations in these genes allow the bacteria to have a higher overall mutation rate and to accumulate mutations that cause drug resistance more quickly

Extensively drug-resistant TB

Main article: Extensively drug-resistant tuberculosis

MDR-TB can become resistant to the major second-line TB drug groups: fluoroquinolones moxifloxacin, ofloxacin and injectable aminoglycoside or polypeptide drugs amikacin, capreomycin, kanamycin When MDR-TB is resistant to at least one drug from each group, it is classified as extensively drug-resistant tuberculosis XDR-TB

In a study of MDR-TB patients from 2005 to 2008 in various countries, 437% had resistance to at least one second-line drug About 9% of MDR-TB cases are resistant to a drug from both classes and classified as XDR-TB

In the past 10 years TB strains have emerged in Italy, Iran, India, and South Africa which are resistant to all available first and second line TB drugs, classified as totally drug-resistant tuberculosis, though there is some controversy over this term Increasing levels of resistance in TB strains threaten to complicate the current global public health approaches to TB control New drugs are being developed to treat extensively resistant forms but major improvements in detection, diagnosis, and treatment will be needed


There are several ways that drug resistance to TB, and drug resistance in general, can be prevented:

  1. Rapid diagnosis & treatment of TB: One of the greatest risk factors for drug resistant TB is problems in treatment and diagnosis, especially in developing countries If TB is identified and treated soon, drug resistance can be avoided
  2. Completion of treatment: Previous treatment of TB is an indicator of MDR TB If the patient does not complete his/her antibiotic treatment, or if the physician does not prescribe the proper antibiotic regimen, resistance can develop Also, drugs that are of poor quality or less in quantity, especially in developing countries, contribute to MDR TB
  3. Patients with HIV/AIDS should be identified and diagnosed as soon as possible They lack the immunity to fight the TB infection and are at great risk of developing drug resistance
  4. Identify contacts who could have contracted TB: ie family members, people in close contact, etc
  5. Research: Much research and funding is needed in the diagnosis, prevention and treatment of TB and MDR TB

"Opponents of a universal tuberculosis treatment, reasoning from misguided notions of cost-effectiveness, fail to acknowledge that MDRTB is not a disease of poor people in distant places The disease is infectious and airborne Treating only one group of patients looks inexpensive in the short run, but will prove disastrous for all in the long run"— Paul Farmer


Community-based treatment programs such as DOTS-Plus, a MDR-TB-specialized treatment using the popular Directly Observed Therapy – Short Course DOTS initiative, have shown considerable success in the of the world In these locales, these programs have proven to be a good option for proper treatment of MDR-TB in poor, rural areas A successful example has been in Lima, Peru, where the program has seen cure rates of over 80%

However, TB clinicians have expressed concern in the DOTS program administered in the Republic of Georgia because it is anchored in a passive case finding This means that the system depends on patients coming to health care providers, without conducting compulsory screenings As medical anthropologists like Erin Koch have shown, this form of implementation does not suit all cultural structures They urge that the DOTS protocol be constantly reformed in the context of local practices, forms of knowledge and everyday life

Erin Koch has utilized Paul Farmer's concept of "structural" violence as a perspective for understanding how "institutions, environment, poverty, and power reproduce, solidify, and naturalize the uneven distribution of disease and access to resources" She has also studied the effectiveness of the DOTS protocol in the widespread disease of tuberculosis in the Georgian prison system Unlike the DOTS passive case finding utilized for the general Georgian public, the multiple-level surveillance in the prison system has proven more successful in reducing the spread of tuberculosis while increasing rates of cure

Koch critically notes that because the DOTS protocol aims to change the individual's behavior without addressing the need to change the institutional, political, and economic contexts, certain limitations arise, such as MDR tuberculosis

Paul Farmer believes that DOTS should be the cornerstone of tuberculosis control around the world


See also: Tuberculosis treatment

Usually, multidrug-resistant tuberculosis can be cured with long treatments of second-line drugs, but these are more expensive than first-line drugs and have more adverse effects The treatment and prognosis of MDR-TB are much more akin to those for cancer than to those for infection MDR-TB has a mortality rate of up to 80%, which depends on a number of factors, including

  1. How many drugs the organism is resistant to the fewer the better
  2. How many drugs the patient is given patients treated with five or more drugs do better
  3. Whether an injectable drug is given or not it should be given for the first three months at least
  4. The expertise and experience of the physician responsible
  5. How co-operative the patient is with treatment treatment is arduous and long, and requires persistence and determination on the part of the patient
  6. Whether the patient is HIV positive or not HIV co-infection is associated with an increased mortality

The majority of patients suffering from multi-drug-resistant tuberculosis do not receive treatment, as they are found in underdeveloped countries or in poverty Denial of treatment remains a difficult human rights issue, as the high cost of second-line medications often precludes those who cannot afford therapy

A study of cost-effective strategies for tuberculosis control supported three major policies First, the treatment of smear-positive cases in DOTS programs must be the foundation of any tuberculosis control approach, and should be a basic practice for all control programs Second, there is a powerful economic case for treating smear-negative and extra-pulmonary cases in DOTS programs along with treating smear-negative and extra-pulmonary cases in DOTS programs as a new WHO "STOP TB" approach and the second global plan for tuberculosis control Last, but not least, the study shows that significant scaling up of all interventions is needed in the next 10 years if the millennium development goal and related goals for tuberculosis control are to be achieved If the case detection rate can be improved, this will guarantee that people who gain access to treatment facilities are covered and that coverage is widely distributed to people who do not now have access

In general, treatment courses are measured in months to years; MDR-TB may require surgery, and death rates remain high despite optimal treatment However, good outcomes for patients are still possible

The treatment of MDR-TB must be undertaken by physicians experienced in the treatment of MDR-TB Mortality and morbidity in patients treated in non-specialist centers are significantly higher to those of patients treated in specialist centers Treatment of MDR-TB must be done on the basis of sensitivity testing: it is impossible to treat such patients without this information When treating a patient with suspected MDR-TB, pending the result of laboratory sensitivity testing, the patient could be started on SHREZ Streptomycin+ isonicotinyl Hydrazine+ Rifampicin+Ethambutol+ pyraZinamide and moxifloxacin with cycloserine There is evidence that previous therapy with a drug for more than a month is associated with diminished efficacy of that drug regardless of in vitro tests indicating susceptibility Hence, a detailed knowledge of the treatment history of each patient is essential In addition to the obvious risks ie, known exposure to a patient with MDR-TB, risk factors for MDR-TB include HIV infection, previous incarceration, failed TB treatment, failure to respond to standard TB treatment, and relapse following standard TB treatment

A gene probe for rpoB is available in some countries This serves as a useful marker for MDR-TB, because isolated RMP resistance is rare except when patients have a history of being treated with rifampicin alone If the results of a gene probe rpoB are known to be positive, then it is reasonable to omit RMP and to use SHEZ+MXF+cycloserine The reason for maintaining the patient on INH is that INH is so potent in treating TB that it is foolish to omit it until there is microbiological proof that it is ineffective even though isoniazid resistance so commonly occurs with rifampicin resistance

When sensitivities are known and the isolate is confirmed as resistant to both INH and RMP, five drugs should be chosen in the following order based on known sensitivities:

  • an aminoglycoside eg, amikacin, kanamycin or polypeptide antibiotic eg, capreomycin
  • pyrazinamide
  • ethambutol
  • a fluoroquinolone eg, moxifloxacin ciprofloxacin should no longer be used;
  • rifabutin
  • cycloserine
  • a thioamide: prothionamide or ethionamide
  • PAS
  • a macrolide: eg, clarithromycin
  • linezolid
  • high-dose INH if low-level resistance
  • interferon-γ
  • thioridazine
  • Ampicillin

Note: Drugs placed nearer the top of the list are more effective and less toxic; drugs placed nearer the bottom of the list are less effective or more toxic, or more difficult to obtain

In general, resistance to one drug within a class means resistance to all drugs within that class, but a notable exception is rifabutin: Rifampicin-resistance does not always mean rifabutin-resistance, and the laboratory should be asked to test for it It is possible to use only one drug within each drug class If it is difficult finding five drugs to treat then the clinician can request that high-level INH-resistance be looked for If the strain has only low-level INH-resistance resistance at 02 mg/l INH, but sensitive at 10 mg/l INH, then high dose INH can be used as part of the regimen When counting drugs, PZA and interferon count as zero; that is to say, when adding PZA to a four-drug regimen, another drug must be chosen to make five It is not possible to use more than one injectable STM, capreomycin or amikacin, because the toxic effect of these drugs is additive: If possible, the aminoglycoside should be given daily for a minimum of three months and perhaps thrice weekly thereafter Ciprofloxacin should not be used in the treatment of tuberculosis if other fluoroquinolones are available

There is no intermittent regimen validated for use in MDR-TB, but clinical experience is that giving injectable drugs for five days a week because there is no-one available to give the drug at weekends does not seem to result in inferior results Directly observed therapy helps to improve outcomes in MDR-TB and should be considered an integral part of the treatment of MDR-TB

Response to treatment must be obtained by repeated sputum cultures monthly if possible Treatment for MDR-TB must be given for a minimum of 18 months and cannot be stopped until the patient has been culture-negative for a minimum of nine months It is not unusual for patients with MDR-TB to be on treatment for two years or more

Patients with MDR-TB should be isolated in negative-pressure rooms, if possible Patients with MDR-TB should not be accommodated on the same ward as immunosuppressed patients HIV-infected patients, or patients on immunosuppressive drugs Careful monitoring of compliance with treatment is crucial to the management of MDR-TB and some physicians insist on hospitalisation if only for this reason Some physicians will insist that these patients remain isolated until their sputum is smear-negative, or even culture-negative which may take many months, or even years Keeping these patients in hospital for weeks or months on end may be a practical or physical impossibility, and the final decision depends on the clinical judgement of the physician treating that patient The attending physician should make full use of therapeutic drug monitoring in particular, of the aminoglycosides both to monitor compliance and to avoid toxic effects

Some supplements may be useful as adjuncts in the treatment of tuberculosis, but, for the purposes of counting drugs for MDR-TB, they count as zero if four drugs are already in the regimen, it may be beneficial to add arginine or vitamin D or both, but another drug will be needed to make five

  • arginine peanuts are a good source
  • vitamin D
  • Dzherelo
  • V5 Immunitor

The drugs listed below have been used in desperation, and it is uncertain as to whether they are effective at all They are used when it is not possible to find five drugs from the list above

  • imipenem
  • co-amoxiclav
  • clofazimine
  • prochlorperazine
  • metronidazole

On 28 December 2012, the US Food and Drug Administration FDA approved bedaquiline marketed as Sirturo by Johnson & Johnson to treat multi-drug resistant tuberculosis, the first new treatment in 40 years Sirturo is to be used in a combination therapy for patients who have failed standard treatment and have no other options Sirturo is an adenosine triphosphate synthase ATP synthase inhibitor

The following drugs are experimental compounds that are not commercially available, but may be obtained from the manufacturer as part of a clinical trial or on a compassionate basis Their efficacy and safety are unknown:

  • pretomanid manufactured by Novartis, developed in partnership with TB Alliance
  • delamanid

In cases of extremely resistant disease, surgery to remove infection portions of the lung is, in general, the final option The center with the largest experience in this is the National Jewish Medical and Research Center in Denver, Colorado In 17 years of experience, they have performed 180 operations; of these, 98 were lobectomies and 82 were pneumonectomies There is a 33% operative mortality, with an additional 68% dying following the operation; 12% experienced significant morbidity in particular, extreme breathlessness Of 91 patients who were culture-positive before surgery, only 4 were culture-positive after surgery

The resurgence of tuberculosis in the United States, the advent of HIV-related tuberculosis, and the development of strains of TB resistant to the first-line therapies developed in recent decades—serve to reinforce the thesis that Mycobacterium tuberculosis, the causative organism, makes its own preferential option for the poor The simple truth is that almost all tuberculosis deaths result from a lack of access to existing effective therapy


Cases of MDR tuberculosis have been reported in every country surveyed MDR-TB most commonly develops in the course of TB treatment, and is most commonly due to doctors giving inappropriate treatment, or patients missing doses or failing to complete their treatment Because MDR tuberculosis is an airborne pathogen, persons with active, pulmonary tuberculosis caused by a multidrug-resistant strain can transmit the disease if they are alive and coughing TB strains are often less fit and less transmissible, and outbreaks occur more readily in people with weakened immune systems eg, patients with HIV Outbreaks among non immunocompromised healthy people do occur, but are less common

As of 2013, 37% of new tuberculosis cases have MDR-TB Levels are much higher in those previously treated for tuberculosis - about 20% WHO estimates that there were about 05 million new MDR-TB cases in the world in 2011 About 60% of these cases occurred in Brazil, China, India, the Russian Federation and South Africa alone In Moldova, the crumbling health system has led to the rise of MDR-TB In 2013, the Mexico–United States border was noted to be "a very hot region for drug resistant TB", though the number of cases remained small

It has been known for many years that INH-resistant TB is less virulent in guinea pigs, and the epidemiological evidence is that MDR strains of TB do not dominate naturally A study in Los Angeles, California, found that only 6% of cases of MDR-TB were clustered Likewise, the appearance of high rates of MDR-TB in New York City in the early 1990s was associated with the explosion of AIDS in that area In New York City, a report issued by city health authorities states that fully 80 percent of all MDR-TB cases could be traced back to prisons and homeless shelters When patients have MDR-TB, they require longer periods of treatment—about two years of multidrug regimen Several of the less powerful second-line drugs, which are required to treat MDR-TB, are also more toxic, with side effects such as nausea, abdominal pain, and even psychosis The Partners in Health team had treated patients in Peru who were sick with strains that were resistant to ten and even twelve drugs Most such patients require adjuvant surgery for any hope of a cure

Russian prisons

One of the so-called "hot-spots" of drug-resistant tuberculosis is within the Russian prison system Infectious disease researchers Nachega & Chaisson report that 10% of the one million prisoners within the system have active TB One of their studies found that 75% of newly diagnosed inmates with TB are resistant to at least one drug; 40% of new cases are multi-drug resistant In 1997, TB accounted for almost half of all Russian prison deaths, and as Bobrik et al point out in their public health study, the 90% reduction in TB incidence contributed to a consequential fall in the prisoner death rate in the years following 1997 Baussano et al articulate that concerning statistics like these are especially worrisome because spikes in TB incidence in prisons are linked to corresponding outbreaks in surrounding communities Additionally, rising rates of incarceration, especially in Central Asian and Eastern European countries like Russia, have been correlated with higher TB rates in civilian populations Even as the DOTS program is expanded throughout Russian prisons, researchers such as Shin et al have noted that wide-scale interventions have not had their desired effect, especially with regard to the spread of drug-resistant strains of TB

Contributing factors

There are several elements of the Russian prison system that enable the spread of MDR-TB and heighten its severity Overcrowding in prisons is especially conducive to the spread of tuberculosis; an inmate in a prison hospital has on average 3 meters of personal space, and an inmate in a correctional colony has 2 meters Specialized hospitals and treatment facilities within the prison system, known as TB colonies, are intended to isolate infected prisoners to prevent transmission; however, as Ruddy et al demonstrate, there are not enough of these colonies to sufficiently protect staff and other inmates Additionally, many cells lack adequate ventilation, which increases likelihood of transmission Bobrik et al have also noted food shortages within prisons, which deprive inmates of the nutrition necessary for healthy functioning

Comorbidity of HIV within prison populations has also been shown to worsen health outcomes Nachega & Chaisson articulate that while HIV-infected prisoners are not more susceptible MDR-TB infection, they are more likely to progress to serious clinical illness if infected According to Stern, HIV infection is 75 times more prevalent in Russian prison populations than in the civilian population Therefore, prison inmates are both more likely to become infected with MDR-TB initially and to experience severe symptoms because of previous exposure to HIV

Shin et al emphasize another factor in MDR-TB prevalence in Russian prisons: alcohol and substance use Ruddy et al showed that risk for MDR-TB is three times higher among recreational drug users than non-users Shin et al's study demonstrated that alcohol usage was linked to poorer outcomes in MDR-TB treatment; they also noted that a majority of subjects within their study many of whom regularly used alcohol were nevertheless cured by their aggressive treatment regimen

Non-compliance with treatment plans is often cited as a contributor to MDR-TB transmission and mortality Indeed, of the 80 newly-released TB-infected inmates in Fry et al's study, 738% did not report visiting a community dispensary for further treatment Ruddy et al cite release from facilities as one of the main causes of interruption in prisoner's TB treatment, in addition to non-compliance within the prison and upon reintegration into civilian life Fry et al's study also listed side effects of TB treatment medications especially in HIV positive individuals, financial worries, housing insecurities, family problems, and fear of arrest as factors that prevented some prisoners from properly adhering to TB treatment They also note that some researchers have argued that the short-term gains TB-positive prisoners receive, such as better food or work exclusion, may dis-incentivize becoming cured In their World Health Organization article, Gelmanova et al posit that non-adherence to TB treatment indirectly contributes to bacterial resistance Although ineffective or inconsistent treatment does not "create" resistant strains, mutations within the high bacterial load in non-adherent prisoners can cause resistance

Nachega & Chaisson argue that inadequate TB control programs are the strongest driver of MDR-TB incidence They note that prevalence of MDR-TB is 25 times higher in areas of poorly controlled TB Russian-based therapy ie, not DOTS has been criticized by Kimerling et al as “inadequate” in properly controlling TB incidence and transmission Bobrik et al note that treatment for MDR-TB is equally inconsistent; the second-line drugs used to treat the prisoners lack specific treatment guidelines, infrastructure, training, or follow-up protocols for prisoners reentering civilian life

Policy impacts

As Ruddy et al note in their scholarly article, Russia's recent penal reforms will greatly reduce the number of inmates inside prison facilities and thus increase the number of ex-convicts integrated into civilian populations Because the incidence of MDR-TB is strongly predicted by past imprisonment, the health of Russian society will be greatly impacted by this change Formerly incarcerated Russians will re-enter civilian life and remain within that sphere; as they live as civilians, they will infect others with the contagions they were exposed to in prison Researcher Vivian Stern argues that the risk of transmission from prison populations to the general public calls for an integration of prison healthcare and national health services to better control both TB and MDR-TB While second-line drugs necessary for treating MDR-TB are arguably more expensive than a typical regimen of DOTS therapy, infectious disease specialist Paul Farmer posits that the outcome of leaving infected prisoners untreated could cause a massive outbreak of MDR-TB in civilian populations, thereby inflicting a heavy toll on society Additionally, as MDR-TB spreads, the threat of the emergence of totally-drug-resistant TB becomes increasingly apparent

See also

  • 2007 tuberculosis scare
  • Drug resistance
  • MRSA
  • Vancomycin-resistant enterococcus VRE
  • Totally drug-resistant tuberculosis TDR-TB


  1. ^ a b c d "Diagnosis and notification of multidrug-resistant TB" PDF WHO Retrieved 7 December 2016 
  2. ^ a b Longo, Fausci; et al 2012 Harrison's Principles of Internal Medicine 18th ed New York: McGraw Hill pp Chapter 165: Tuberculosis Retrieved 7 Dec 2016 
  3. ^ "Chapter 168 Antimycobacterial Agents | Harrison's Principles of Internal Medicine, 18e" AccessMedicine | McGraw-Hill Medical Retrieved 2016-12-07 
  4. ^ a b c d Wood, Alastair JJ; Iseman, Michael D 1993 "Treatment of Multidrug-Resistant Tuberculosis" New England Journal of Medicine 329 11: 784–91 doi:101056/NEJM199309093291108 PMID 8350889 
  5. ^ Stoffels, Karolien; Allix-Béguec, Caroline; Groenen, Guido; Wanlin, Maryse; Berkvens, Dirk; Mathys, Vanessa; Supply, Philip; Fauville-Dufaux, Maryse 2013-05-09 "From Multidrug- to Extensively Drug-Resistant Tuberculosis: Upward Trends as Seen from a 15-Year Nationwide Study" PLOS ONE 8 5: e63128 doi:101371/journalpone0063128 ISSN 1932-6203 
  6. ^ Parwati, Ida; Crevel, Reinout van; Soolingen, Dick van "Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains" The Lancet Infectious Diseases 10 2: 103–111 doi:101016/s1473-30990970330-5 
  7. ^ a b c d Millard, James; Ugarte-Gil, Cesar; Moore, David A J 2015-02-26 "Multidrug resistant tuberculosis" BMJ 350: h882 doi:101136/bmjh882 ISSN 1756-1833 PMID 25721508 
  8. ^ a b c Adams and Woelke 2014 Understanding Global Health Chapter 10: TB and HIV/AIDS 12th ed McGraw Hill Retrieved 9 May 2015 
  9. ^ Keshavjee, Salmaan; Farmer, Paul E 2012-09-06 "Tuberculosis, Drug Resistance, and the History of Modern Medicine" New England Journal of Medicine 367 10: 931–936 doi:101056/NEJMra1205429 ISSN 0028-4793 PMID 22931261 
  10. ^ Kaplan, Jeffrey 2017 "Tuberculosis" American University Lecture
  11. ^ Nathanson, Eva; Nunn, Paul; Uplekar, Mukund; Floyd, Katherine; Jaramillo, Ernesto; Lönnroth, Knut; Weil, Diana; Raviglione, Mario 2010-09-09 "MDR Tuberculosis — Critical Steps for Prevention and Control" New England Journal of Medicine 363 11: 1050–1058 doi:101056/NEJMra0908076 ISSN 0028-4793 PMID 20825317 
  12. ^ "Multi-drug-resistant tuberculosis MDR-TB – 2015 Update" WHO Retrieved 7 December 2016 
  13. ^ Sandhu, P; Akhter, Y 26 September 2017 "Evolution of structural fitness and multifunctional aspects of mycobacterial RND family transporters" Archives of Microbiology doi:101007/s00203-017-1434-6 PMID 28951954 
  14. ^ Louw, G E; Warren, R M; Gey Van Pittius, N C; McEvoy, C R E; Van Helden, P D; Victor, T C 2009 "A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance" Antimicrobial Agents and Chemotherapy 53 8: 3181–9 doi:101128/AAC01577-08 PMC 2715638  PMID 19451293 
  15. ^ Gillespie, S H 2002 "Evolution of Drug Resistance in Mycobacterium tuberculosis: Clinical and Molecular Perspective" Antimicrobial Agents and Chemotherapy 46 2: 267–74 doi:101128/AAC462267-2742002 PMC 127054  PMID 11796329 
  16. ^ Ramaswamy, S; Musser, JM 1998 "Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update" Tubercle and Lung Disease 79 1: 3–29 doi:101054/tuld19980002 PMID 10645439 
  17. ^ Baptista, Rafael; Bhowmick, Sumana; Nash, Robert J; Baillie, Les; Mur, Luis AJ 2018-03-23 "Target discovery focused approaches to overcome bottlenecks in the exploitation of antimycobacterial natural products" Future Medicinal Chemistry doi:104155/fmc-2017-0273 
  18. ^ Hanekom, M; Pittius, NC Gey van; McEvoy, C; Victor, TC; Helden, PD Van; Warren, RM "Mycobacterium tuberculosis Beijing genotype: A template for success" Tuberculosis 91 6: 510–523 doi:101016/jtube201107005 
  19. ^ Ford, Christopher B; Shah, Rupal R; Maeda, Midori Kato; Gagneux, Sebastien; Murray, Megan B; Cohen, Ted; Johnston, James C; Gardy, Jennifer; Lipsitch, Marc July 2013 "Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug resistant tuberculosis" Nature Genetics 45 7: 784–790 doi:101038/ng2656 ISSN 1061-4036 PMC 3777616  PMID 23749189 
  20. ^ Mestre, Olga; Luo, Tao; Vultos, Tiago Dos; Kremer, Kristin; Murray, Alan; Namouchi, Amine; Jackson, Céline; Rauzier, Jean; Bifani, Pablo 2011-01-20 "Phylogeny of Mycobacterium tuberculosis Beijing Strains Constructed from Polymorphisms in Genes Involved in DNA Replication, Recombination and Repair" PLOS ONE 6 1: e16020 doi:101371/journalpone0016020 ISSN 1932-6203 
  21. ^ Dalton, Tracy; Cegielski, Peter; Akksilp, Somsak; Asencios, Luis; Caoili, Janice Campos; Cho, Sang-Nae; Erokhin, Vladislav V; Ershova, Julia; Gler, Ma Tarcela; Kazennyy, Boris Y; Kim, Hee Jin; Kliiman, Kai; Kurbatova, Ekaterina; Kvasnovsky, Charlotte; Leimane, Vaira; Van Der Walt, Martie; Via, Laura E; Volchenkov, Grigory V; Yagui, Martin A; Kang, Hyungseok; Global Petts, Investigators; Akksilp, R; Sitti, W; Wattanaamornkiet, W; Andreevskaya, SN; Chernousova, LN; Demikhova, OV; Larionova, EE; Smirnova, TG; Vasilieva, IA 2012 "Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: A prospective cohort study" The Lancet 380 9851: 1406–17 doi:101016/S0140-67361260734-X PMID 22938757 
  22. ^ a b WHO "Multidrug-resistant tuberculosis MDR-TB 2013 Update" PDF World Health Organization Retrieved 14 June 2013 
  23. ^ Velayati, A; Farnia P; Masjedi M 2013 "The totally drug resistant tuberculosis TDR-TB" International Journal of Clinical and Experimental Medicine 6 4: 307–309 
  24. ^ a b Zumla, Alimuddin; Abubakar, Ibrahim; Raviglione, Mario; Hoelscher, Michael; Ditiu, Lucica; Mchugh, Timothy D; Squire, S Bertel; Cox, Helen; Ford, Nathan 2012-05-15 "Drug-Resistant Tuberculosis—Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs" Journal of Infectious Diseases 205 suppl 2: S228–S240 doi:101093/infdis/jir858 ISSN 0022-1899 PMID 22476720 
  25. ^ Parida, S K; Axelsson-Robertson, R; Rao, M V; Singh, N; Master, I; Lutckii, A; Keshavjee, S; Andersson, J; Zumla, A 2015-04-01 "Totally drug-resistant tuberculosis and adjunct therapies" Journal of Internal Medicine 277 4: 388–405 doi:101111/joim12264 ISSN 1365-2796 
  26. ^ Gao, Qian; Li, Xia 2010 "Transmission of MDR tuberculosis" Drug Discovery Today: Disease Mechanisms 7: e61–5 doi:101016/jddmec201009006 
  27. ^ Lobue, Philip 2009 "Extensively drug-resistant tuberculosis" Current Opinion in Infectious Diseases 22 2: 167–73 doi:101097/QCO0b013e3283229fab PMID 19283912 
  28. ^ Farmer 2005, p 133
  29. ^ Shin, Sonya; Furin, Jennifer; Bayona, Jaime; Mate, Kedar; Kim, Jim Yong; Farmer, Paul 2004 "Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience" Social Science & Medicine 59 7: 1529–39 doi:101016/jsocscimed200401027 PMID 15246180 
  30. ^ Koch, Erin 2011 "Local Microbiologies of Tuberculosis: Insights from the Republic of Georgia" Medical Anthropology 30 1: 81–101 doi:101080/014597402010531064 PMID 21218357 
  31. ^ Koch, Erin 2006 "Beyond suspicion" American Ethnologist 33: 50–62 doi:101525/ae200633150 
  32. ^ "Scientific Facts on Drug-resistant Tuberculosis" GreenFacts 2008-12-18 Retrieved 2009-03-26 
  33. ^ a b c Farmer, Paul 2001 "The Major Infectious Diseases in the World — to Treat or Not to Treat" New England Journal of Medicine 345 3: 208–10 doi:101056/NEJM200107193450310 PMID 11463018 
  34. ^ Baltussen, R; Floyd, K; Dye, C 2005 "Cost effectiveness analysis of strategies for tuberculosis control in developing countries" BMJ 331 7529: 1364 doi:101136/bmj3864566009368 PMC 1309642  PMID 16282379 
  35. ^ Mitnick, Carole; Bayona, Jaime; Palacios, Eda; Shin, Sonya; Furin, Jennifer; Alcántara, Felix; Sánchez, Epifanio; Sarria, Madeleny; Becerra, Mercedes; Fawzi, Mary C Smith; Kapiga, Saidi; Neuberg, Donna; Maguire, James H; Kim, Jim Yong; Farmer, Paul 2003 "Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru" New England Journal of Medicine 348 2: 119–28 doi:101056/NEJMoa022928 PMID 12519922 
  36. ^ Goble, Marian; Iseman, Michael D; Madsen, Lorie A; Waite, Dennis; Ackerson, Lynn; Horsburgh Jr, C Robert 1993 "Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin" New England Journal of Medicine 328 8: 527–32 doi:101056/NEJM199302253280802 PMID 8426619 
  37. ^ Steering Group; Ernesto Jaramillo 2008 Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008 Geneva, Switzerland: World Health Organization p 51 ISBN 978-92-4-154758-1 
  38. ^ Ziganshina, LE; Vizel, AA; Squire, SB 2005 Ziganshina, Lilia, ed "Fluoroquinolones for treating tuberculosis" Cochrane Database of Systematic Reviews 3: CD004795 doi:101002/14651858CD004795pub2 PMID 16034951 
  39. ^ Leimane, Vaira; Riekstina, Vija; Holtz, Timothy H; Zarovska, Evija; Skripconoka, Vija; Thorpe, Lorna E; Laserson, Kayla F; Wells, Charles D 2005 "Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: A retrospective cohort study" The Lancet 365 9456: 318–26 doi:101016/S0140-67360517786-1 PMID 15664227 
  40. ^ Schon, T; Elias, D; Moges, F; Melese, E; Tessema, T; Stendahl, O; Britton, S; Sundqvist, T 2003 "Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis" European Respiratory Journal 21 3: 483–8 doi:101183/090319360300090702 PMID 12662006 
  41. ^ Rockett, Kirk A; Brookes, Roger; Udalova, Irina; Vidal, Vincent; Hill, Adrian V S; Kwiatkowski, Dominic 1998 "1,25-Dihydroxyvitamin D3 Induces Nitric Oxide Synthase and Suppresses Growth of Mycobacterium tuberculosis in a Human Macrophage-Like Cell Line" Infection and Immunity 66 11: 5314–21 PMC 108664  PMID 9784538 
  42. ^ Zaitzeva, S I; Matveeva, S L; Gerasimova, T G; Pashkov, Y N; Butov, D A; Pylypchuk, V S; Frolov, V M; Kutsyna, G A 2009 "Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo" Clinical Microbiology and Infection 15 12: 1154–62 doi:101111/j1469-0691200902760x PMID 19456829 
  43. ^ Butov, Dmitry A; Pashkov, Yuri N; Stepanenko, Anna L; Choporova, Aleksandra I; Butova, Tanya S; Batdelger, Dendev; Jirathitikal, Vichai; Bourinbaiar, Aldar S; Zaitzeva, Svetlana I 2011 "Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant MDR TB" Journal of Immune Based Therapies and Vaccines 9: 3 doi:101186/1476-8518-9-3 PMC 3031205  PMID 21244690 
  44. ^ Chambers, H F; Turner, J; Schecter, G F; Kawamura, M; Hopewell, P C 2005 "Imipenem for Treatment of Tuberculosis in Mice and Humans" Antimicrobial Agents and Chemotherapy 49 7: 2816–21 doi:101128/AAC4972816-28212005 PMC 1168716  PMID 15980354 
  45. ^ Chambers, Henry F; Kocagöz, Tanil; Sipit, Tugrul; Turner, Joan; Hopewell, Philip C 1998 "Activity of Amoxicillin/Clavulanate in Patients with Tuberculosis" Clinical Infectious Diseases 26 4: 874–7 doi:101086/513945 PMID 9564467 
  46. ^ Peter r Donald, Frederick a Sirge; Sirgel, FA; Venter, A; Parkin, DP; Van De Wal, BW; Barendse, A; Smit, E; Carman, D; Talent, J; Maritz, J 2001 "Early Bactericidal Activity of Amoxicillin in Combination with Clavulanic Acid in Patients with Sputum Smear-positive Pulmonary Tuberculosis" Scandinavian Journal of Infectious Diseases 33 6: 466–9 doi:101080/00365540152029954 PMID 11450868 
  47. ^ Jagannath, C; Reddy, M V; Kailasam, S; O'Sullivan, J F; Gangadharam, P R 1995 "Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis In vitro, intracellular, and in vivo studies" American Journal of Respiratory and Critical Care Medicine 151 4: 1083–6 doi:101164/ajrccm15147697235 PMID 7697235 
  48. ^ Adams, Linda B; Sinha, Indu; Franzblau, Scott G; Krahenbuhl, James L Krahenbuhl; Mehta, Reeta T Mehta 1999 "Effective Treatment of Acute and Chronic Murine Tuberculosis with Liposome-Encapsulated Clofazimine" Antimicrobial Agents and Chemotherapy 43 7: 1638–43 PMC 89336  PMID 10390215 
  49. ^ Janulionis, E; Sofer, C; Song, H-Y; Wallis, R S 2004 "Lack of Activity of Orally Administered Clofazimine against Intracellular Mycobacterium tuberculosis in Whole-Blood Culture" Antimicrobial Agents and Chemotherapy 48 8: 3133–5 doi:101128/AAC4883133-31352004 PMC 478499  PMID 15273133 
  50. ^ Shubin, H; Sherson, J; Pennes, E; Glaskin, A; Sokmensuer, A 1958 "Prochlorperazine compazine as an aid in the treatment of pulmonary tuberculosis" Antibiotic Medicine and Clinical Therapy 5 5: 305–9 PMID 13521769 
  51. ^ Wayne, L G; Sramek, H A 1994 "Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis" Antimicrobial Agents and Chemotherapy 38 9: 2054–8 doi:101128/AAC3892054 PMC 284683  PMID 7811018 
  52. ^ "FDA Press Release" US Food and Drug Administration 31 December 2012 
  53. ^ Carroll, John 31 December 2012 "J&J wins accelerated OK for first new TB drug in 40 years" fiercebiotechcom Retrieved 3 January 2013 
  54. ^ Stover, C Kendall; Warrener, Paul; Vandevanter, Donald R; Sherman, David R; Arain, Taraq M; Langhorne, Michael H; Anderson, Scott W; Towell, J Andrew; Yuan, Ying; McMurray, David N; Kreiswirth, Barry N; Barry, Clifton E; Baker, William R 2000 "A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis" Nature 405 6789: 962–6 doi:101038/35016103 PMID 10879539 
  55. ^ Chase, Marilyn 27 October 2004 "Novartis Sets Deal to Seek New Drugs for Fighting TB" TB Alliance Archived from the original on 6 May 2007 Retrieved 3 January 2013 
  56. ^ Farmer 1999, p 
  57. ^ Farmer 2005, p 148
  58. ^ Centers for Disease Control CDC August 1991 "Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons—Florida and New York, 1988–1991" Morbidity and Mortality Weekly Report 40 34: 585–91 PMID 1870559 
  59. ^ Edlin, Brian R; Tokars, Jerome I; Grieco, Michael H; Crawford, Jack T; Williams, Julie; Sordillo, Emelia M; Ong, Kenneth R; Kilburn, James O; Dooley, Samuel W; Castro, Kenneth G; Jarvis, William R; Holmberg, Scott D 1992 "An Outbreak of Multidrug-Resistant Tuberculosis among Hospitalized Patients with the Acquired Immunodeficiency Syndrome" New England Journal of Medicine 326 23: 1514–21 doi:101056/NEJM199206043262302 PMID 1304721 
  60. ^ Pitchenik, Arthure; Burr, Janice; Laufer, Marla; Miller, Gary; Cacciatore, Robert; Bigler, Williamj; Witte, Johnj; Cleary, Timothy 1990 "Outbreaks of drug-resistant tuberculosis at AIDS centre" The Lancet 336 8712: 440–1 doi:101016/0140-67369091987-L PMID 1974967 
  61. ^ Centers for Disease Control CDC March 1991 "Transmission of multidrug-resistant tuberculosis from an HIV-positive client in a residential substance-abuse treatment facility—Michigan" Morbidity and Mortality Weekly Report 40 8: 129–31 PMID 1900098 
  62. ^ Fischl, Margaret A; Uttamchandani, RB; Daikos, GL; Poblete, RB; Moreno, JN; Reyes, RR; Boota, AM; Thompson, LM; Cleary, TJ; Lai, S 1992 "An Outbreak of Tuberculosis Caused by Multiple-Drug-resistant Tubercle Bacilli among Patients with HIV Infection" Annals of Internal Medicine 117 3: 177–83 doi:107326/0003-4819-117-3-177 PMID 1616211 
  63. ^ Centers for Disease Control 1990 "Outbreak of multidrug-resistant tuberculosis—Texas, California, and Pennsylvania" Morbidity and Mortality Weekly Report 39 22: 369–72 PMID 2111434 
  64. ^ Rochkind, David "Moldova: Fighting a Deadly Disease" Pulitzer Center on Crisis Reporting Retrieved 23 September 2012 
  65. ^ McKay, Betsy March 9–10, 2013 "Risk of Deadly TB Exposure Grows Along US—Mexico Border" The Wall Street Journal paper p A1 
  66. ^ Frieden, Thomas R; Sterling, Timothy; Pablos-Mendez, Ariel; Kilburn, James O; Cauthen, George M; Dooley, Samuel W 1993 "The Emergence of Drug-Resistant Tuberculosis in New York City" New England Journal of Medicine 328 8: 521–6 doi:101056/NEJM199302253280801 PMID 8381207 
  67. ^ Garrett 2000, p 266ff
  68. ^ Garrett 1994, p 524
  69. ^ Farmer 2005, p 118
  70. ^ a b c d e Nachega J, Chaisson R 2003 "Tuberculosis Drug Resistance: A Global Threat" Clinical Infectious Diseases 36 1: S24–S30 doi:101086/344657 
  71. ^ a b c d e Bobrik A; Danishevski K; Eroshina K; McKee M 2005 "Prison Health in Russia: The Larger Picture" Journal of Public Health Policy 26 1: 30–59 doi:101057/palgravejphp3200002 
  72. ^ Baussano I; Williams B; Nunn P; Beggiato M; Fedeli U 2010 "Tuberculosis Incidence in Prisons: A Systematic Review" PLOS Medicine 7 12: e1000381 doi:101371/journalpmed1000381 
  73. ^ a b c Shin S S; Pasechnikov A; Gelmanova I; Peremitin G; Strelis A; Andreev Y; Golubchikova V; Tonkel T; Yanova G; Nikiforov M; Yedilbayev A; Mukherjee J; Furin J; Barry D; Farmer P; Rich M; Keshavjee S 2006 "Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia" The International Journal of Tuberculosis and Lung Disease 10 4: 402–407 
  74. ^ a b c d e Ruddy M; Balabanova Y; Graham C; Fedorin I; Malomanova N; Elisarova E; Kuznetznov S; Gusarova G; Zakharova S; Melentyev A; Krukova E; Golishevskaya V; Erokhin V; Dorozhkova I; Drobniewski F 2005 "Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samar Region, Russia" Thorax 60 2: 130–135 doi:101136/thx2004026922 
  75. ^ a b Stern, V 2001 Problems in Prisons Worldwide, with a Particular Focus on Russia Annals of the New York Academy of Sciences, 953b, 113-119
  76. ^ a b c Fry R; Khoshnood K; Vdovichenko E; Granskaya J; Sazhin V; Shpakovskaya L; Zhemkov V; Zhemkova M; Rowhani-Rahbar A; Funk M; Kozlov A 2005 "Barriers to completion of tuberculosis treatment among prisoners and former prisoners in St Petersburg, Russia" The International Journal of Tuberculosis and Lung Disease 9 9: 1027–1033 
  77. ^ Gelmanova I; Keshavjee S; Golubchikova V; Berezina V; Strelis A; Yanova G; Atwood S; Murray M 2007 "Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance" Bulletin of the World Health Organization 85: 9 
  78. ^ Kimerling ME; Kluge H; Vezhnina N; Iacovazzi T; Demeulenaere T; Portaels F; Matthys F 1999 "Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB" The International Journal of Tuberculosis and Lung Disease 3 5: 451–453 
  79. ^ Farmer P 1999 "Pathologies of power: rethinking health and human rights" American Journal of Public Health 89 10: 1486–1496 doi:102105/ajph89101486 
  • Farmer, Paul 1999 Infections and inequalities : the modern plagues Berkeley, California, United States: University of California Press ISBN 978-0-520-22913-6 
  • Farmer, Paul 2005 Pathologies of Power: health, human rights, and the new war on the poor Berkeley, California, United States: University of California Press ISBN 978-0-520-93147-3 
  • Garrett, Laurie 1994 The coming plague : newly emerging diseases in a world out of balance New York, New York, United States: Farrar, Straus and Giroux ISBN 978-0-374-12646-9 
  • Garrett, Laurie 2000 Betrayal of trust: the collapse of global public health New York, New York, United States: Hyperion Books ISBN 978-0-7868-6522-2 

External links

  • Video: Drug-Resistant TB in Russia 24 July 2007, Woodrow Wilson Center event featuring Salmaan Keshavjee and Murray Feshbach
  • TB Drug Resistance Mutation Database
  • MDR-TB : a story of Hope, Struggle & Triumph
  • MDR-TB DOTS Plus protocol followed under RNTCP in India PDF
  • "The Strange, Isolated Life of a Tuberculosis Patient in the 21st Century", Buzzfeed

multi-drug-resistant tuberculosis, what is multi-drug-resistant tuberculosis

Multi-drug-resistant tuberculosis Information about

Multi-drug-resistant tuberculosis

  • user icon

    Multi-drug-resistant tuberculosis beatiful post thanks!


Multi-drug-resistant tuberculosis
Multi-drug-resistant tuberculosis
Multi-drug-resistant tuberculosis viewing the topic.
Multi-drug-resistant tuberculosis what, Multi-drug-resistant tuberculosis who, Multi-drug-resistant tuberculosis explanation

There are excerpts from wikipedia on this article and video

Random Posts

Timeline beyond October following the September 11 attacks

Timeline beyond October following the September 11 attacks

The following list contains certain dates beyond October 2001 involving the September 11 attacks ...
Smash Hits

Smash Hits

Smash Hits was a pop music magazine, aimed at teenagers and young adults and originally published in...
2014–15 USC Trojans women's basketball team

2014–15 USC Trojans women's basketball team

The 2014–15 USC Trojans women's basketball team will represent University of Southern California dur...
Trademark classification

Trademark classification

A trademark classification is a way the trademark examiners and applicants' trademark attorneys arra...